Foslevodopa

CHEMBL4594379 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
277.2 g/mol
LogP
-4.0
Phase
4

A prodrug form of levodopa delivered under the skin to provide steady levels of the medication for Parkinson's disease. It helps reduce motor fluctuations in patients who experience unpredictable 'on' and 'off' periods.

Peso molecular

277,1700 g/mol

LogP

-4,00

TPSA

150,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O

InChI

InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1

Molecular Formula

C9H12NO7P

HBD / HBA

5 / 8

Enlaces Rotables

5

Átomos Pesados

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A prodrug form of levodopa delivered under the skin to provide steady levels of the medication for Parkinson's disease. It helps reduce motor fluctuations in patients who experience unpredictable 'on' and 'off' periods.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Foslevodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594379. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 127766. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.